BPC-157 Tracker App
Log Every Dose, Track Healing Milestones, and Monitor Your Protocol
BPC-157 (Body Protection Compound-157) is a 15-amino-acid peptide derived from a gastroprotective protein in gastric juice. It is one of the most studied healing peptides in preclinical research, with applications spanning tendon and ligament repair, gut wall integrity, nerve regeneration, and muscle healing. Shotlee lets you track injections, oral dosing, pain scores, gut symptoms, and range of motion — all in one free app.
15,000+
Peptide Users
4.8★
App Rating
Free
Always Free
What Is BPC-157?
BPC-157 is a synthetic pentadecapeptide (15 amino acids) derived from a partial sequence of Body Protection Compound, a protein naturally found in human gastric juice. In preclinical models it demonstrates remarkable tissue-healing properties: accelerating tendon-to-bone repair, protecting the gut mucosa from NSAID and alcohol damage, promoting angiogenesis at wound sites, and attenuating inflammatory cytokine cascades.
What makes BPC-157 unusual among peptides is its gastric acid stability. Unlike most peptides that degrade in stomach acid, BPC-157 survives the GI environment — enabling genuine oral bioavailability. This allows two completely different administration routes: subcutaneous or intramuscular injection near the injury site for localised tissue repair, and oral capsule or water solution for systemic gut healing.
Research Peptide — Not for Human Use
BPC-157 is not approved for human use by the FDA or in most jurisdictions. All evidence comes from animal models and preclinical research. Consult a licensed physician before considering any peptide protocol.
Protocol Options
250 mcg
Subcutaneous, once daily
Low-end injectable protocol for tendon, ligament, or muscle injury. Injected near the site of injury for localised healing effect.
500 mcg
Subcutaneous or IM, once daily
Standard injectable dose for more significant injuries or systemic anti-inflammatory effects. Common 4–12 week cycle.
1,000 mcg
Oral (capsule/water), twice daily
Oral protocol for gut healing applications (IBD, leaky gut, NSAID-induced damage). BPC-157 is acid-stable and survives gastric passage.
Mechanism of Action
Upregulates growth hormone receptor expression in tendon fibroblasts — amplifies local GH-driven repair signalling without systemic GH elevation.
Stimulates angiogenesis at wound sites by activating VEGF pathways, increasing blood supply and nutrient delivery to injured tissue.
Modulates nitric oxide (NO) synthesis to regulate vascular tone and reduce ischaemic damage in healing tissue.
Suppresses NF-κB-mediated inflammatory cytokine production, reducing TNF-α and IL-6 at the injury site while preserving necessary healing inflammation.
Research Highlights
Tendon Healing
2x
Preclinical data shows roughly double the tendon-to-bone re-attachment rate vs controls at 3 weeks post-transection in rat models.
Gut Protection
99%
Near-complete cytoprotection against NSAID-induced gut ulceration observed in multiple rodent models at low mcg/kg doses.
What to Track in Shotlee
Build a complete healing diary — injections, symptoms, and progress metrics in one place.
Injection Logs
Record every dose: date, amount (mcg), route (subQ/IM/oral), and reconstitution batch. Never lose your protocol history.
Injection Site Rotation
Track which sites you rotate through to avoid lipodystrophy and ensure even tissue exposure near the injury.
Wound & Pain Rating
Log daily pain scores (0–10) at the target injury site. Watch scores decline over weeks as healing progresses.
Gut Symptom Diary
For oral protocols: log bloating, cramping, stool consistency, and frequency to document gut healing response.
Range of Motion
Measure and log joint range of motion (degrees) at each checkpoint to objectively track musculoskeletal recovery.
Healing Progress Photos
Attach timestamped photos of wounds or injury sites to create a visual healing timeline alongside your dose logs.
Oral vs Injectable: Choosing Your Route
The route of administration significantly changes the therapeutic target. Subcutaneous injection close to an injury site concentrates BPC-157 locally — useful for tendon, ligament, muscle, and nerve injuries. Intramuscular injection works similarly. Both routes are typically dosed at 250–500 mcg per day over a 4–12 week cycle.
Oral BPC-157 (capsule or dissolved in water on an empty stomach) targets the gut. Because the peptide is stable in gastric acid — a rare property — it reaches the intestinal mucosa intact. Research protocols for gut healing typically use 500–1000 mcg twice daily. Some researchers split dosing: morning oral for gut, localised injection for musculoskeletal injury, running both simultaneously.
Track Route in Shotlee
Log whether each dose was oral, subcutaneous, or IM in Shotlee. If you run dual protocols, separate logs help you attribute effects accurately.
Protocol FAQs
In preclinical research, BPC-157 is studied for tendon and ligament repair, gut mucosal healing (IBD, leaky gut, NSAID-induced damage), muscle healing, nerve regeneration, and anti-inflammatory effects. It is not approved for human use.
Yes. BPC-157 is unusually stable in gastric acid, which allows it to survive stomach passage and reach the intestinal mucosa intact. Oral dosing is specifically used for gut-targeted applications, typically 500–1000 mcg twice daily.
Injectable protocols commonly use 250–500 mcg per day subcutaneously or IM, injected near the injury site. Oral gut protocols typically use 500–1000 mcg twice daily. Cycle length is typically 4–12 weeks depending on the healing target.
Preclinical studies show measurable tissue repair markers within 1–2 weeks. Most researchers report subjective improvements in pain and mobility within 2–4 weeks for musculoskeletal applications, and gut symptom improvements within 1–3 weeks for oral gut protocols. Track your progress in Shotlee for a personalised timeline.
BPC-157 and TB-500 are frequently combined in research protocols because they act through complementary mechanisms — BPC-157 via GH receptor and angiogenesis pathways, TB-500 via actin upregulation and cell migration. There is no clinical trial data on this combination in humans. Log each compound separately in Shotlee.
References
- [1]ReviewSikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Curr Pharm Des. 2011;17(16):1612-32.
- [2]ReviewChang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011;110(3):774-80.
- [3]ReviewGwyer D, et al. "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing." Cell Tissue Res. 2019;377(2):153-159.
Track Your BPC-157 Protocol in Shotlee
Log every dose, track pain scores, document gut symptoms, and measure healing progress — all in the free Shotlee app.
🚀 Use Shotlee for Free